Minutes Board Meeting MultiPark
2012-02-29 kl 14.00-16.30

Present: Hjalmar Bjartmarz
         Martha Escobar
         Oskar Hansson
         Susanne Iwarsson (Chair)
         Zuzanna Kurowska
         Elisabet Londos
         Per Odin
         Roger Olsson
         Jens Schouenborg

Absent:  Anders Björklund
         Cecilia Lundberg
         Ingemar Carlstedt

§1. Opening of the Meeting
Susanne Iwarsson welcomed everybody and opened the meeting. As for March the 1st
Ingemar Carlstedt will step down as representative of the Faculty of Medicine, his
replacement has not been assigned yet. It was also mentioned that Oskar Hansson has
become a new member of the board in his role as assistant coordinator.

§2. Introduction of Zuzanna Kurowska, new member of the board (PhD student
representative)
Susanne Iwarsson introduced Zuzanna Kurowska, and all the present members of the board
introduced themselves.

§3. Election of "Justeringsperson"
Oskar Hansson was assigned as "Justeringsperson".

§4. Approval of the agenda
The content of the agenda was approved, but the order of the points was changed; §8
would be taken after §13.

§5. Delegated decisions (enclosure 1)
The travel grants approved by the coordinator/assistant coordinator are listed in enclosure
1.

§6. Decisions per capita (enclosure 2)
As summarized in the tables in enclosure 2, the budget for 2012 and the appointment of
Swedish referees for clinical positions were approved.

§7. Information
- Update on recruitments
  Administration. Susanne Iwarsson reported on the process leading to the recruitment
  replacing Martha Escobar, who will be in leave absence for 2 years. She also informed
about that Emma Roybon will have the main responsibility for the MultiPark administration.

**Professorship in clinical neuroscience.** Approved by the Faculty Board with minor changes – the position will be advertised labeled "clinical neuroscience", without the specialization in movement disorders. In addition, the Faculty Board requires that MultiPark guarantees to finance the position up to 80%, adhering to the general funding principles for faculty-funded professorships.

**Professorship in chemical biology and drug discovery.** The process is ongoing and the Faculty reckons that an appointment would be possible from July 1st 2012, provided the process continues as planned.

*Regarding the common funds at university level.* Susanne Iwarsson described the efforts by the coordinators of the strategic areas to get an idea of how the Vice-chancellor will utilize the 5% of the funding budgeted at university level. She informed about an initiative that will be taken by the Vice-chancellor office to open a call for applications from the coordinators of the strategic research areas. In order to be prepared for such an application from MultiPark, suggestions from the board members are welcome (submitted via e-mail to Susanne Iwarsson/Martha Escobar by March 20, 2012).

**§8. Decision regarding increasing the level of funding of the clinical professorship from 70% to 80%, in case the professor is a holder of a 3-year grant from specified funding bodies.**

In order to follow the general model of funding of professorships at the faculty according to the request by the Faculty Board, it was decided to increase the level of funding from 70 to 80%, provided the person employed is holding the type of external grant required to attain this higher level of funding.

**§9. Discussion and decision on four 50% clinical research positions**

Following a discussion on potential conflicts of interest, Susanne Iwarsson, Oskar Hansson, Elisabet Londos and Hjalmar Bjartmarz declared that they have such a conflict regarding these recruitments, while Zuzanna Kurowska, Roger Olsson, Jens Schouenborg and Per Odin did not.

Since there was no quorum to make any decision during this meeting, it was agreed to first have a general discussion regarding the procedure, involving all board members present. It was discussed that the ranking based on the referees’ evaluation should be followed. In addition, it was agreed to accomplish personal interviews with the candidates to clarify the plans and prerequisites for how their research should be carried out. Thereafter, the board members with a conflict of interest left the room and the discussion on the procedure continued. The outcome of this discussion was the following:

1. An interview should be carried out with the 4 or 5 top candidates.
2. It is important to keep in mind that we have up to 4 positions to fill and that if not all positions are filled at this time it might be of strategic importance to re-allocate the resources for other kinds of positions. If this will be the case, following further strategic discussions, this requires new decisions in the Board.
c. The 50% research positions cannot be reduced in time, and the person who receives such a position must devote 50% of their working hours for research performed at Lund University.

Finally, it was decided by the board to support the points pointed out by the group and that a committee consisting of Per Odin (chair), Jens Schouenborg and Zuzanna Kurowska is responsible for carrying out the interviews and presenting a suggestion for the decision to the Board, to be distributed at the prospect of the next meeting. It was also agreed that, in case the procedure gets completed well ahead of the next board meeting, the final decision will be made at an extra meeting (not per capsular).

§10. Discussion and decision on principles for travel funding (enclosure 5).
It was decided to continue with the travel grants as carried out until now, but that their advertisement should be intensified. Also, it was decided that until otherwise decided, there will be no limitations for an individual researcher or a research group to receive repeated grants.

§11. Discussion and decision on the termination of ALF-support.
It was decided to discontinue this kind of support since the MultiPark funding period is 2010-2014 and successful applicants to “Yngre-ALF” during 2012 will consequently need to be awarded grants that will extend beyond this limit.

§12. Discussion and decision on the third-year postdoc funding mechanism.
It was decided to discontinue this form of funding for junior scientists as a consequence of the changes in the ordinance regulating teacher positions at the university. In addition, it was also decided to terminate the so-called “returning postdoc” funding since the same rules regarding employment apply for these. Moreover, since its establishment only one application has been submitted and funded. Consequently, it was agreed that there is a need to find alternative solutions, and as part of the now intensified discussions on how to use the funding from 2012 and onwards (see §14), the principles and mechanisms for funding of postdocs will be revised.

Susanne Iwarsson went through the budget that has been updated in terms of the progress of the recruitment, the decisions taken since December 2011, and the final balance of 2011. The revised budget shows a positive balance (ca 6 million SEK specified as “buffer”). It was decided to approve the revised budget and to keep the “buffer” as well as the resources previously used for postdoctoral positions (see §12), open for suggestions to be made by the PIs and associated partners (see §14).

Susanne Iwarsson informed about the initiatives taken for improving the internal information, including feedback from the two meetings held since the beginning of the year (one for PIs and one open information meeting). The next meeting, open for PIs and associated partners, is scheduled for March 21, at 9.30-11.30 am. Important aspects to be discussed is the definition of the strategic research area of neuroscience/MultiPark (for 2012-2014 and 2015 and onwards), principles for budgeting (e.g. new forms of funding for different types of positions, infrastructure, PhD student employment support, new professorship in experimental sciences), and appointment of a Scientific Advisory Board.

[Signature]
§15. Other issues
No other issues were discussed.

Susanne Iwansson  
Chairman

Martha Escobar

Justeras 2012-03-19

Oskar Hansson
Delegated decisions

Travel grants

<table>
<thead>
<tr>
<th>Applicant</th>
<th>Max amount (SEK)</th>
<th>Kind of activity</th>
<th>Approved by</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erik Hellman</td>
<td>15 000</td>
<td>Visit to SHS in USA to carry out tritium effluxmetry measurements on alpha-synuclein association with model lipid membranes</td>
<td>S Isachsen</td>
<td>2011-11-15</td>
</tr>
<tr>
<td>Marie Grey</td>
<td>15 000</td>
<td>Visit to SHS in USA to carry out tritium effluxmetry measurements on alpha-synuclein association with model lipid membranes</td>
<td>S Isachsen</td>
<td>2011-12-01</td>
</tr>
<tr>
<td>Marie Grey</td>
<td>15 000</td>
<td>Biophysical Society 56th Annual Meeting in San Diego, USA, February 23-26, 2012</td>
<td>S Isachsen</td>
<td>2011-12-09</td>
</tr>
<tr>
<td>Agneta Halsby</td>
<td>15 000</td>
<td>IUPAC meeting in Tokyo, Japan</td>
<td>S Isachsen</td>
<td>2012-02-15</td>
</tr>
<tr>
<td>Emanuel Hagel</td>
<td>3 330</td>
<td>IUPAC conference &quot;Proteopathic Toxins and Neurodegenerative Diseases&quot;</td>
<td>S Isachsen</td>
<td>2012-02-20</td>
</tr>
<tr>
<td>Christopher Buzing</td>
<td>4 000</td>
<td>IUPAC conference &quot;Proteopathic Toxins and Neurodegenerative Diseases&quot;</td>
<td>S Isachsen</td>
<td>2012-02-20</td>
</tr>
</tbody>
</table>

Decisions per capsulam

Approval of the budget 2012; HCS-budget 2011/2012; ALF-support

<table>
<thead>
<tr>
<th>Conflict of Interest</th>
<th>Approved by</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>The board</td>
<td>2011-12-04</td>
</tr>
</tbody>
</table>

Approval of the appointment of Swedish referees for clinical positions

<table>
<thead>
<tr>
<th>Conflict of Interest</th>
<th>Approved by</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>The board</td>
<td>2012-01-30</td>
</tr>
</tbody>
</table>